2025-10-06
Regulatory
EQL Pharma is recruiting a new CCO with an international background as part of its new five-year plan. This means that the current Chief Commercial Officer (CCO) Alexander Brising will leave his po...
2025-09-30
Regulatory
During September 2025, the number of shares and votes in EQL Pharma AB (“EQL Pharma”) has increased as a result of the exercise of warrants issued pursuant to two warrant programs adopted by the an...
2025-09-23
EQL's key product Mellozzan[®] (tablets) has now been launched in the UK by our partner Medice. Medice specialise in ADHD and have previously launched Mellozzan[®] successfully in Germany, among ot...